Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000338149 | SCV000336433 | uncertain significance | not provided | 2015-10-26 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001043855 | SCV001207622 | benign | Bethlem myopathy 1A | 2025-01-06 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000338149 | SCV001999716 | uncertain significance | not provided | 2019-12-05 | criteria provided, single submitter | clinical testing | In silico analysis, which includes splice predictors and evolutionary conservation, suggests this variant may impact gene splicing. In the absence of RNA/functional studies, the actual effect of this sequence change is unknown.; Has not been previously published as pathogenic or benign to our knowledge |
Ce |
RCV000338149 | SCV004146748 | likely benign | not provided | 2023-11-01 | criteria provided, single submitter | clinical testing | COL6A1: BP4, BP7 |
Prevention |
RCV004543036 | SCV004782359 | uncertain significance | not specified | 2023-10-18 | no assertion criteria provided | clinical testing | The COL6A1 c.1437C>T variant is not predicted to result in an amino acid change (p.=). This variant is predicted to possibly create a donor site within the exon and may result in aberrant splicing (Alamut Visual Plus v1.6.1). To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.012% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/21-47417373-C-T). Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |